The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion.
Key result
Streptokinase did not significantly reduce left ventricular infarct size compared to control (13.0% vs 13.4%; p=NS) or exacerbate gross hemorrhage (5.7% vs 6.5%) during coronary reperfusion.
Why the study?
Does streptokinase exacerbate intramyocardial hemorrhage, affect infarct size, or abolish the no-reflow phenomenon in a canine model of coronary reperfusion?
Population
Anesthetized open-chest dogs undergoing coronary occlusion for 3 hours followed by 3 hours of reperfusion
Comparison
Streptokinase vs Control (untreated)
Design
Preclinical
Follow-up
3 hours of reperfusion
Authors
Discussion
Loading...
Member takes
Implication
Streptokinase shows no infarct size benefit or hemorrhage risk in canine reperfusion; leaves open translation to human no-reflow or clinical use.
Structured PICO
Does streptokinase exacerbate intramyocardial hemorrhage, affect infarct size, or abolish the no-reflow phenomenon in a canine model of coronary reperfusion?
P
Population
Anesthetized open-chest dogs undergoing coronary occlusion for 3 hours followed by 3 hours of reperfusion (n=16)
I
Intervention
Streptokinase
C
Comparator
Control (untreated)
O
Outcome
Intramyocardial hemorrhage, infarct size, and no-reflow phenomenonsurrogate
Main Result
Absolute Event Rate: 13% vs 13.4%
p-value: p=NS
In a canine model of ischemia-reperfusion, streptokinase did not exacerbate intramyocardial hemorrhage, reduce infarct size, or prevent the no-reflow phenomenon.
Cite This Study
Kloner et al. (1984) studied Coronary occlusion and reperfusion (n=16). Streptokinase vs. Control (untreated) was evaluated on Area of infarction of the left ventricle (p=NS). Streptokinase did not significantly reduce left ventricular infarct size compared to control (13.0% vs 13.4%; p=NS) or exacerbate gross hemorrhage (5.7% vs 6.5%) during coronary reperfusion.